NAS:PLRX (USA)
Business Description
Pliant Therapeutics Inc
NAICS : 541714
SIC : 2833
260 Littlefield Avenue, South San Francisco, CA, USA, 94080
Compare
Compare
Traded in other countries / regions
9PT.Germany
•
PLRX.USA
Description
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.02 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 12.68 | |||||
| Beneish M-Score | -1.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.5 | |||||
| 3-Year EPS without NRI Growth Rate | -8.4 | |||||
| 3-Year FCF Growth Rate | -5.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.61 | |||||
| 9-Day RSI | 54.38 | |||||
| 14-Day RSI | 58.27 | |||||
| 6-1 Month Momentum % | 99.39 | |||||
| 12-1 Month Momentum % | 4.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.69 | |||||
| Quick Ratio | 7.69 | |||||
| Cash Ratio | 7.25 | |||||
| Days Sales Outstanding | 86.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.8 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1112.67 | |||||
| Net Margin % | -1109.19 | |||||
| ROE % | -55.44 | |||||
| ROA % | -49.98 | |||||
| ROIC % | -788.76 | |||||
| ROC (Joel Greenblatt) % | -1335.74 | |||||
| ROCE % | -54.18 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 74.04 | |||||
| PB Ratio | 4.94 | |||||
| Price-to-Tangible-Book | 4.7 | |||||
| EV-to-EBIT | -7.62 | |||||
| EV-to-Forward-EBIT | -0.55 | |||||
| EV-to-EBITDA | -7.73 | |||||
| EV-to-Revenue | 84.96 | |||||
| EV-to-Forward-Revenue | 93.96 | |||||
| EV-to-FCF | -9.12 | |||||
| Price-to-Net-Current-Asset-Value | 5.13 | |||||
| Price-to-Net-Cash | 5.54 | |||||
| Earnings Yield (Greenblatt) % | -13.09 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:PLRX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.847 | ||
| EPS (TTM) ($) | -3.03 | ||
| Beta | 0 | ||
| Volatility % | 136.62 | ||
| 14-Day RSI | 58.27 | ||
| 14-Day ATR ($) | 1.46857 | ||
| 20-Day SMA ($) | 18.9185 | ||
| 12-1 Month Momentum % | 4.24 | ||
| 52-Week Range ($) | 3.965 - 24.17 | ||
| Shares Outstanding (Mil) | 48.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pliant Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||